I’ve a piece up at The New Yorker on 23andMe’s clash with the FDA: Here’s the opening: The United States Food and Drug Administration is not known for its prose. So the warning letter that it sent to 23andMe, the direct-to-consumer genetic-testing company, on November 22nd, was a surprise in more ways than one. “It reads like […]